Monoamine Oxidase Inhibition by Major Tanshinones from Salvia miltiorrhiza and Selective Muscarinic Acetylcholine M-4 Receptor Antagonism by Tanshinone I

Monoamine oxidases (MAOs) and muscarinic acetylcholine receptors (mAChRs) are considered important therapeutic targets for Parkinson's disease (PD). Lipophilic tanshinones are major phytoconstituents in the dried roots of Salvia miltiorrhiza that have demonstrated neuroprotective effects agains...

Full description

Bibliographic Details
Main Authors: Choi, JS (Author), Fauzi, FM (Author), Jung, HA (Author), Park, SE (Author), Paudel, P (Author), Prajapati, R (Author), Seong, SH (Author)
Format: Article
Language:English
Published: 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 02556nam a2200373Ia 4500
001 10.3390-biom11071001
008 220223s2021 CNT 000 0 und d
245 1 0 |a Monoamine Oxidase Inhibition by Major Tanshinones from Salvia miltiorrhiza and Selective Muscarinic Acetylcholine M-4 Receptor Antagonism by Tanshinone I 
260 0 |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.3390/biom11071001 
520 3 |a Monoamine oxidases (MAOs) and muscarinic acetylcholine receptors (mAChRs) are considered important therapeutic targets for Parkinson's disease (PD). Lipophilic tanshinones are major phytoconstituents in the dried roots of Salvia miltiorrhiza that have demonstrated neuroprotective effects against dopaminergic neurotoxins and the inhibition of MAO-A. Since MAO-B inhibition is considered an effective therapeutic strategy for PD, we tested the inhibitory activities of three abundant tanshinone congeners against recombinant human MAO (hMAO) isoenzymes through in vitro experiments. In our study, tanshinone I (1) exhibited the highest potency against hMAO-A, followed by tanshinone IIA and cryptotanshinone, with an IC50 less than 10 mu M. They also suppressed hMAO-B activity, with an IC50 below 25 mu M. Although tanshinones are known to inhibit hMAO-A, their enzyme inhibition mechanism and binding sites have yet to be investigated. Enzyme kinetics and molecular docking studies have revealed the mode of inhibition and interactions of tanshinones during enzyme inhibition. Proteochemometric modeling predicted mAChRs as possible pharmacological targets of 1, and in vitro functional assays confirmed the selective M-4 antagonist nature of 1 (56.1% +/- 2.40% inhibition of control agonist response at 100 mu M). These findings indicate that 1 is a potential therapeutic molecule for managing the motor dysfunction and depression associated with PD. 
650 0 4 |a DESIGN 
650 0 4 |a DOCKING 
650 0 4 |a DOPAMINERGIC-NEURONS 
650 0 4 |a IIA PROTECTS 
650 0 4 |a M-4 receptor antagonist 
650 0 4 |a MAO-A 
650 0 4 |a MEMORY 
650 0 4 |a MODEL 
650 0 4 |a molecular docking 
650 0 4 |a monoamine oxidase inhibition 
650 0 4 |a Parkinson's disease 
650 0 4 |a PREVENTS 
650 0 4 |a SILICO 
650 0 4 |a tanshinone I 
650 0 4 |a TARGET 
700 1 0 |a Choi, JS  |e author 
700 1 0 |a Fauzi, FM  |e author 
700 1 0 |a Jung, HA  |e author 
700 1 0 |a Park, SE  |e author 
700 1 0 |a Paudel, P  |e author 
700 1 0 |a Prajapati, R  |e author 
700 1 0 |a Seong, SH  |e author 
773 |t BIOMOLECULES